Press Release | ERDERA Clinical Trial Call

ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA has opened its Clinical Trial Call 2026, a funding opportunity for multinational early-phase interventional clinical trials in rare diseases.

The call supports sponsor-led Phase I, Phase I/II and Phase II trials of medicinal products designed to generate robust clinical evidence, strengthen regulatory readiness and improve trial feasibility across countries.

Up to €30 million is dedicated to the call, with individual project budgets broadly expected in the range of €1 million to €5 million.

Acces this publication

publication

ERDERA clinical trial call

Year of publication

2026

Source

ERDERA

Author

ERDERA

You might also be interested in

ERDERA at the WODC

Can AI deliver for rare diseases? ERDERA brings the debate to WODC Europe

ERDERA will return to the World Orphan Drug Congress Europe with a booth and an interactive pre-conference workshop examining where artificial intelligence can support rare disease research and therapeutic development, and where human expertise remains essential.
ERDERA clinical trial call

ERDERA Clinical Trial Call – Model Award Agreement

Model award agreement document setting out the structure, articles and contractual provisions applicable to funded activities.
ERDERA clinical trial call

ERDERA Clinical Trial Call – Annex IV. Guidelines for Canadian Applicants

This annex explains the specific eligibility, sponsorship, funding and application requirements for Canadian applicants in the ERDERA Clinical Trial Call.
ERDERA clinical trial call

ERDERA Clinical Trial Call – Call Text

Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.

ERDERA Search